Obstructive sleep apnea syndrome and fatty liver: Association or causal link?

被引：47
作者：
Ahmed, Mohamed H.
Byrne, Christopher D.
机构：
[1] Chemical Pathology Department, Southampton University Hospital NHS Trust, Southampton
[2] Endocrinology and Metabolism, DOHaD Division, University of Southampton and Southampton University Hospitals Trust, Southampton, SO16 6YD, Mail point 6-Level D, South Academic Block
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2010年 / 16卷 / 34期
关键词：
Sleep apnea syndrome; Hyperlipidemia; Non-alcoholic fatty liver disease; Insulin resistance; TYPE-2; DIABETIC-PATIENTS; CHRONIC INTERMITTENT HYPOXIA; SERUM AMINOTRANSFERASE LEVELS; POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR RISK-FACTORS; CORONARY-ARTERY-DISEASE; ADIPOSE-TISSUE HYPOXIA; FACTOR-KAPPA-B; INSULIN-RESISTANCE; METABOLIC SYNDROME;
D O I：
10.3748/wjg.v16.i34.4243
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Obstructive sleep apnea (OSA) is a complex disorder that consists of upper airway obstruction, chronic intermittent hypoxia and sleep fragmentation. OSA is well known to be associated with hypoxia, insulin resistance and glucose intolerance, and these factors can occur in the presence or absence of obesity and metabolic syndrome. Although it is well established that insulin resistance, glucose intolerance and obesity occur frequently with non-alcoholic fatty liver disease (NAFLD), it is now becoming apparent that hypoxia might also be important in the development of NAFLD, and it is recognized that there is increased risk of NAFLD with OSA. This review discusses the association between OSA, NAFLD and cardiovascular disease, and describes the potential role of hypoxia in the development of NAFLD with OSA. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码：4243 / 4252
页数：10
相关论文
共 106 条
[1]  
Ahmed M.H., 2005, The metabolic syndrome, P279
[2]  
AHMED MH, 2007, YEAR LIPID DISORDERS, P3
[3]  
AHMED MH, 2010, PRIM CARE DIABETES
[4]   Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD) [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DRUG DISCOVERY TODAY, 2007, 12 (17-18) :740-747
[5]   Biochemical markers - The road map for the diagnosis of nonalcoholic fatty liver disease [J].
Ahmed, Mohamed H. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (01) :20-22
[6]   Current treatment of non-alcoholic fatty liver disease [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DIABETES OBESITY & METABOLISM, 2009, 11 (03) :188-195
[7]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[8]   Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients [J].
Antonopoulos, S ;
Mikros, S ;
Mylonopoulou, M ;
Kokkoris, S ;
Giannoulis, G .
ATHEROSCLEROSIS, 2006, 184 (01) :233-234
[9]   ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism [J].
Berg, AH ;
Combs, TP ;
Scherer, PE .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (02) :84-89
[10]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
12345678910